Jerry L Spivak

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint The anaemia of cancer: death by a thousand cuts
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21210, USA
    Nat Rev Cancer 5:543-55. 2005
  2. doi request reprint Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders
    Jerry L Spivak
    Traylor 924 Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Expert Rev Anticancer Ther 11:403-14. 2011
  3. doi request reprint Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation
    Jerry L Spivak
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Ann Intern Med 152:300-6. 2010
  4. ncbi request reprint Maxwell Wintrobe, in his own words
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Br J Haematol 121:224-32. 2003
  5. ncbi request reprint Haematological manifestations of systemic disease
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Med 5:322-5. 2005
  6. doi request reprint Anemia management in oncology and hematology
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21210, USA
    Oncologist 14:43-56. 2009
  7. ncbi request reprint Diagnostic evaluation of the chronic myeloproliferative disorders
    Jerry L Spivak
    Hematology Division, John Hopkins University School of Medicine, Baltimore, MD, USA
    Isr Med Assoc J 4:1028-31. 2002
  8. ncbi request reprint Polycythemia vera: myths, mechanisms, and management
    Jerry L Spivak
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Blood 100:4272-90. 2002
  9. doi request reprint The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Blood 112:231-9. 2008
  10. pmc Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens
    Alison R Moliterno
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Exp Hematol 36:1480-6. 2008

Detail Information

Publications35

  1. ncbi request reprint The anaemia of cancer: death by a thousand cuts
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21210, USA
    Nat Rev Cancer 5:543-55. 2005
    ....
  2. doi request reprint Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders
    Jerry L Spivak
    Traylor 924 Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Expert Rev Anticancer Ther 11:403-14. 2011
    ..The toxicity profile of hydroxycarbamide is also discussed to enable clinicians to balance potential risks with therapeutic benefits...
  3. doi request reprint Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation
    Jerry L Spivak
    Johns Hopkins Medical Institutions, Baltimore, Maryland 21205 2196, USA
    Ann Intern Med 152:300-6. 2010
    ..Preliminary results of clinical trials with agents that inhibit the mutated kinase indicate a reduction in splenomegaly and alleviation of night sweats, fatigue, and pruritus...
  4. ncbi request reprint Maxwell Wintrobe, in his own words
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Br J Haematol 121:224-32. 2003
  5. ncbi request reprint Haematological manifestations of systemic disease
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Med 5:322-5. 2005
  6. doi request reprint Anemia management in oncology and hematology
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21210, USA
    Oncologist 14:43-56. 2009
    ..An update on the management of anemia in oncology, the potential adverse events of ESAs, the benefits and risks of transfusions, and QoL are discussed in this paper...
  7. ncbi request reprint Diagnostic evaluation of the chronic myeloproliferative disorders
    Jerry L Spivak
    Hematology Division, John Hopkins University School of Medicine, Baltimore, MD, USA
    Isr Med Assoc J 4:1028-31. 2002
  8. ncbi request reprint Polycythemia vera: myths, mechanisms, and management
    Jerry L Spivak
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Blood 100:4272-90. 2002
  9. doi request reprint The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Blood 112:231-9. 2008
  10. pmc Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens
    Alison R Moliterno
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Exp Hematol 36:1480-6. 2008
    ..We examined the relationship of the quantitative JAK2(V617F) allele burden to MPD disease phenotype among the three MPD classes and within PV...
  11. pmc Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis
    Donna M Williams
    Johns Hopkins University School of Medicine, Baltimore, MD21205, USA
    Exp Hematol 35:1641-6. 2007
    ..We, therefore, sought to determine whether there were JAK2 or MPL lesions in a well-defined, JAK2 V617F-negative MPD cohort, and to determine if clinical associations could be identified based on variations identified in these genes...
  12. pmc Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders
    Brady L Stein
    Division of Hematology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD, USA
    Haematologica 95:1090-7. 2010
    ..Since variability in the JAK2(V617F) allele burden is partly responsible for the distinct phenotypes seen in the myeloproliferative disorders, the objective of this study was to identify modifiers of the allele burden...
  13. pmc Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
    Alison R Moliterno
    Johns Hopkins University School of Medicine, Ross Research 1025, 720 Rutland Ave, Baltimore, MD 21205, USA
    Blood 108:3913-5. 2006
    ....
  14. pmc Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders
    Zhaohui Ye
    Stem Cell Program, Institute for Cell Engineering, and Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 114:5473-80. 2009
    ..These iPS cells provide a renewable cell source and a prospective hematopoiesis model for investigating MPD pathogenesis...
  15. pmc Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis
    Alison R Moliterno
    Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 101:11444-7. 2004
    ..K39N represents an identified functional Mpl polymorphism and is associated with altered protein expression of Mpl and a clinical phenotype of thrombocytosis...
  16. doi request reprint Treatment of polycythemia vera with imatinib mesylate
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
    Leuk Res 36:156-62. 2012
    ..Therefore, we believe there may be a role for IM in patients with these characteristics whose disease cannot be controlled by, or as an alternative to, other myelosuppressive treatments...
  17. ncbi request reprint Iron and the anemia of chronic disease
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 16:25-33. 2002
    ....
  18. pmc Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
    Maurizio Zangari
    Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA
    Blood Coagul Fibrinolysis 24:311-6. 2013
    ..This retrospective study suggests that even moderate hypoxia associated with 5000 feet elevation should be considered as an independent prothrombotic risk factor. This observation needs to be confirmed by prospective studies...
  19. ncbi request reprint Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Hematology Division, Traylor 924, 720 Rutland Ave, Baltimore, MD 21205, USA
    Semin Hematol 40:1-5. 2003
    ..Enumeration of peripheral blood CD34(+) cells may prove useful in the diagnosis of IMF if current data regarding the disease-related specificity of this measurement are validated prospectively in larger numbers of patients...
  20. ncbi request reprint Hematologic disorders associated with hepatitis C virus infection and their management
    Douglas T Dieterich
    Department of Medicine, Mount Sinai Medical Center, New York, New York, USA
    Clin Infect Dis 37:533-41. 2003
    ..This review highlights the pharmacology, risks, and benefits of recombinant hematopoietic growth factor therapy in HCV-infected patients...
  21. ncbi request reprint The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns
    Michael B Streiff
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 99:1144-9. 2002
    ..A significant minority of physicians undertreat erythrocytosis, and little consensus exists regarding the treatment of thrombocytosis...
  22. doi request reprint Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient-Specific Induced Pluripotent Stem Cells
    Zhaohui Ye
    Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Stem Cell Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Stem Cells 32:269-78. 2014
    ..The iPSC-mediated disease modeling thus underlies the ineffectiveness of the current JAK inhibitors and provides a modeling system to develop better targeted therapies for the JAK2 mutated hematopoiesis. Stem Cells 2014;32:269-278. ..
  23. ncbi request reprint The optimal management of polycythaemia vera
    Jerry L Spivak
    Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Br J Haematol 116:243-54. 2002
  24. doi request reprint Anagrelide: 20 years later
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Expert Rev Anticancer Ther 9:37-50. 2009
    ..In this article, we review anagrelide pharmacology, the physiology of thrombopoiesis, the differential diagnosis of thrombocytosis and the management of patients with an elevated platelet count...
  25. pmc Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
    Brady L Stein
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Thrombosis 2011:874146. 2011
    ..Our analysis contributes to growing literature emphasizing gender differences in the MPN and further supports the important impact of individual and host variation on MPN clinical manifestations, and especially vascular risk...
  26. ncbi request reprint The chronic myeloproliferative disorders: clonality and clinical heterogeneity
    Jerry L Spivak
    Hematology Division, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Semin Hematol 41:1-5. 2004
    ..Currently, given the unresolved issues with respect to the clinical and clonal heterogeneity of the MPD, treatment needs to be tailored individually in patients with an MPD...
  27. ncbi request reprint The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era
    Huichun Zhan
    Sidney Kimmel Comprehensive Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Adv Hematol Oncol 7:334-42. 2009
    ..In this review, we discuss the molecular basis of polycythemia vera, essential thrombocythemia, and primary myelofibrosis, their diagnosis and their management in the context of the JAK2 V617F mutation...
  28. ncbi request reprint Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2
    Jerry L Spivak
    N Engl J Med 355:737; author reply 738. 2006
  29. ncbi request reprint Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels
    Philipp L Goerttler
    Haematologica 90:851-3. 2005
    ..The results of this retrospective analysis must now be corroborated in a large, prospective trial of newly diagnosed patients...
  30. ncbi request reprint Polycythemia vera: scientific advances and current practice
    Ayalew Tefferi
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Semin Hematol 42:206-20. 2005
    ..Despite recent progress in the field, several important issues remain controversial. In this review, we will present the areas of agreement, but also point out where the authors' personal viewpoints differ...
  31. ncbi request reprint Prediction of chemotherapy-induced anaemia: is knowledge really power?
    Jerry L Spivak
    Lancet Oncol 6:822-4. 2005
  32. ncbi request reprint Imatinib mesylate in polycythemia vera
    Jerry L Spivak
    Blood 103:3241; author reply 3241-2. 2004
  33. ncbi request reprint Polycythemia vera and the emperor's new clothes
    Jerry L Spivak
    Haematologica 88:1-4. 2003
  34. ncbi request reprint Anemia in the elderly: time for new blood in old vessels?
    Jerry L Spivak
    Arch Intern Med 165:2187-9. 2005
  35. ncbi request reprint Detection, evaluation, and management of anemia in the elective surgical patient
    Lawrence T Goodnough
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive H 1402, Stanford, CA 94305 5626, USA
    Anesth Analg 101:1858-61. 2005
    ....